Riverhead Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Riverhead Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$98K	Buy	8,483 +2,000	+31%	+$21K	﹤0.01%	1329
2019 Q2	$65K	Buy	6,483 +1,500	+30%	+$16.2K	﹤0.01%	1419
2019 Q1	$64K	Hold	4,983	–	–	﹤0.01%	1411
2018 Q4	$76K	Hold	4,983	–	–	﹤0.01%	1361
2018 Q3	$100K	Hold	4,983	–	–	﹤0.01%	1398
2018 Q2	$97K	Hold	4,983	–	–	﹤0.01%	1350
2018 Q1	$100K	Buy	4,983 +600	+14%	+$10.1K	﹤0.01%	1336
2017 Q4	$58K	Buy	4,383 +1,000	+30%	+$15.1K	﹤0.01%	1454
2017 Q3	$62K	Buy	3,383 +887	+36%	+$16.5K	﹤0.01%	1411
2017 Q2	$46K	Buy	2,496 +1,296	+108%	+$25.7K	﹤0.01%	1428
2017 Q1	$27K	Buy	1,200 +100	+9%	+$2.39K	﹤0.01%	1420
2016 Q4	$38K	Hold	1,100	–	–	﹤0.01%	1303
2016 Q3	$27K	Sell	1,100 -191,320	-99%	-$4.78M	﹤0.01%	1334
2016 Q2	$2.4M	Buy	192,420 +188,895	+5,359%	+$4.33M	0.08%	283
2016 Q1	$83K	Buy	+3,525	New	+$83.7K	﹤0.01%	1349

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Riverhead Capital Management's AMAG Position: Q3 2019 in Review

Riverhead Capital Management increased its AMAG Pharmaceuticals (AMAG) stake by 31% in Q3 2019, buying an estimated $21K and bringing the position to 8,483 shares worth $98K. The position accounts for ﹤0.01% of the portfolio, ranked #1329.

Riverhead Capital Management first reported a position in AMAG in Q1 2016 and has held it in 15 quarters since. The position peaked at $2.4M in Q2 2016. 156 funds tracked by Wall St. Rank hold AMAG as of Q3 2019.

Riverhead Capital Management held 8,483 shares of AMAG Pharmaceuticals worth $98K as of Q3 2019.
Riverhead Capital Management bought 2,000 AMAG Pharmaceuticals shares in Q3 2019, an estimated $21K.
AMAG Pharmaceuticals made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1329 holding.
Riverhead Capital Management first reported a position in AMAG Pharmaceuticals in Q1 2016 and has held it in 15 quarters since.
Riverhead Capital Management's AMAG Pharmaceuticals position peaked at $2.4M in Q2 2016.
156 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.